

Multiple dosing mitigates ASA hyporesponsiveness after CABG

March 22 2017



(HealthDay)—Acetylsalicylic acid (ASA) hyporesponsiveness after



coronary artery bypass graft (CABG) surgery can be overcome by multiple dosing, according to a study published online March 7 in the *Journal of Thrombosis and Haemostasis*.

Jeremy S. Paikin, M.D., from McMaster University in Hamilton, Canada, and colleagues randomized 68 adults undergoing CABG surgery to receive ASA 81 mg once-daily, 325 mg once-daily, or 162 mg twicedaily. Median serum thromboxane B_2 (TXB₂) level was measured on postoperative day four. The results were pooled with those of an earlier study to better assess the effect of ASA 325 mg once-daily or divided doses.

The researchers found that patients randomized to ASA 81 mg oncedaily had a median day four TXB_2 level of 4.2 ng/mL, compared with 1.1 ng/mL among those randomized to ASA 162 mg twice-daily and 1.9 ng/mL among those randomized to 325 mg once-daily. In pooled data, groups receiving ASA 162 mg twice-daily or 81 mg four times-daily had a median TXB_2 level of 1.1 ng/mL compared with 2.2 ng/mL among those receiving ASA 325 mg once-daily.

"Multiple daily dosing of ASA is more effective than ASA 81 mg oncedaily or 325 mg once-daily at suppressing serum TXB₂ formation after CABG surgery," the authors write. "A twice-daily treatment regimen needs to be tested in a clinical outcome study."

The study was funded by <u>research grants</u> from <u>pharmaceutical</u> <u>companies</u>.

More information: <u>Abstract</u> <u>Full Text (subscription or payment may be required)</u>

Copyright © 2017 HealthDay. All rights reserved.



Citation: Multiple dosing mitigates ASA hyporesponsiveness after CABG (2017, March 22) retrieved 27 April 2024 from https://medicalxpress.com/news/2017-03-multiple-dosing-mitigates-asa-hyporesponsiveness.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.